NLS drug-2

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon in adults with Primary IgA nephropathy (IgAN). The Phase 3 trial met the primary endpoint, estimated glomerular filtration rate (eGFR), with Nefecon demonstrating significant kidney protective effect over placebo, states the company in a press […]

Annexin Pharmaceuticals has announced that an independent evaluation of potential signals of effect has been carried out in the company’s Phase 2-study in retinal vein occlusion with the investigational new drug ANXV. Positive findings justify an extended follow-up period, states the company. “With these early signals in the RVO study, a favorable safety profile and […]

Ultimovacs has announced the completion of enrollment of 75 patients and that the last patient has received the first dose in the FOCUS study. “We are pleased to announce the completion of patient enrollment in the FOCUS trial, the third of five randomized Phase II clinical trials evaluating UV1 in different cancer indications and in […]

Bavarian Nordic has announced topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle (VLP)-based chikungunya virus vaccine candidate, CHIKV VLP, in adults and adolescents aged 12 to 64 years of age. A total of 3,254 participants were enrolled and randomized to receive either a single intramuscular injection of CHIKV […]

Alligator Bioscience has announced positive second interim results from the ongoing OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb agonist) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal […]

Bavarian Nordic has reported results from a Phase 3 non-inferiority clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The two-part study enrolled a total of 4,205 adults who either previously completed primary vaccination or had already received one booster dose of a licensed COVID-19 vaccine. The active, controlled part enrolled 622 participants […]